Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine
- PMID: 24704709
- DOI: 10.3851/IMP2771
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine
Abstract
Background: The prevalence of rilpivirine resistance-associated mutations (RAMs) in the USA, and their effect on phenotypic susceptibility to rilpivirine and etravirine, was evaluated in clinical samples from HIV-1-infected patients.
Methods: In total, 15,991 samples submitted to Monogram Biosciences (South San Francisco, CA, USA) for routine resistance testing between January 2010 and June 2011 were assessed for the presence of known rilpivirine RAMs K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L; non-nucleoside reverse transcriptase inhibitor (NNRTI) RAMs K103N, L100I and L100I+K103N; and the nucleoside reverse transcriptase inhibitor (NRTI) RAMs M184I/V and their combinations with rilpivirine RAMs. Phenotypic susceptibility (PhenoSenseGT(®) assay; Monogram Biosciences) was evaluated, with reduced susceptibility defined as fold change (FC) in 50% inhibitory concentration (IC50)>2.0 for rilpivirine and FC>2.9 for etravirine.
Results: Of the 15,991 samples, 17% harboured ≥1 rilpivirine RAMs. The prevalence of most rilpivirine RAMs and combinations of NNRTI RAMs of interest was low (≤3%), except for Y181C (7%). Rilpivirine RAMs were often associated with reduced rilpivirine phenotypic susceptibility. Median FC values >2.0 were observed for clinical isolates with rilpivirine RAMs K101P, E138Q/R, Y181C/I/V, Y188L or M230L, and for the combination of E138K with M184I/V, and K101E with M184I. Most rilpivirine FC values >2.0 were associated with etravirine FC values >2.9 for individual rilpivirine RAMs and those combined with M184I/V. There was no relationship between the presence of K103N and rilpivirine FC. However, the L100I+K103N combination (without rilpivirine RAMs), at <2% prevalence, was associated with a rilpivirine FC>2.0.
Conclusions: Based on 15,991 US clinical samples from HIV-1-infected patients, the frequency of most known rilpivirine RAMs apart from Y181C was low.
Similar articles
-
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29. J Antimicrob Chemother. 2013. PMID: 23361642
-
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395. Epub 2014 Oct 25. J Antimicrob Chemother. 2015. PMID: 25344807 Clinical Trial.
-
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.AIDS. 2013 Jan 2;27(1):81-5. doi: 10.1097/QAD.0b013e3283584500. AIDS. 2013. PMID: 22842995
-
[Resistance profile of rilpivirine].Enferm Infecc Microbiol Clin. 2013 Jun;31 Suppl 2:36-43. doi: 10.1016/S0213-005X(13)70141-1. Enferm Infecc Microbiol Clin. 2013. PMID: 24252532 Review. Spanish.
-
Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.J Antimicrob Chemother. 2013 Feb;68(2):250-6. doi: 10.1093/jac/dks404. Epub 2012 Oct 25. J Antimicrob Chemother. 2013. PMID: 23099850 Review.
Cited by
-
2022 update of the drug resistance mutations in HIV-1.Top Antivir Med. 2022 Oct;30(4):559-574. Top Antivir Med. 2022. PMID: 36375130 Free PMC article.
-
Development of HIV Drug-Resistance Mutations and Antiretroviral Efficacy Among Vietnamese Patients After Failure of 5-Year First-Line Therapy.J Clin Lab Anal. 2025 Mar;39(5):e25157. doi: 10.1002/jcla.25157. Epub 2025 Feb 5. J Clin Lab Anal. 2025. PMID: 39907180 Free PMC article.
-
Characterization of Human Immunodeficiency Virus-1 Transmission Clusters and Transmitted Drug-Resistant Mutations in Croatia from 2019 to 2022.Viruses. 2023 Dec 11;15(12):2408. doi: 10.3390/v15122408. Viruses. 2023. PMID: 38140649 Free PMC article.
-
APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants.Front Virol. 2022;2:919825. doi: 10.3389/fviro.2022.919825. Epub 2022 Jul 14. Front Virol. 2022. PMID: 35957953 Free PMC article.
-
Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.Retrovirology. 2016 Feb 16;13:11. doi: 10.1186/s12977-016-0244-2. Retrovirology. 2016. PMID: 26880034 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical